10-KPeriod: FY2012

DEXCOM INC Annual Report, Year Ended Dec 31, 2012

Filed February 21, 2013For Securities:DXCM

Summary

DexCom, Inc. reported its 2012 annual results, highlighting significant progress in its continuous glucose monitoring (CGM) technology. The company received FDA approval for its fourth-generation G4 PLATINUM system in October 2012, a key advancement designed for improved accuracy, a sleeker receiver, and better sensor performance. This new system is poised to be a primary revenue driver, with marketing efforts shifting from the older SEVEN PLUS model. The company also expanded its reach by securing CE Mark approval for the G4 system in Europe and other international markets. Financially, DexCom saw a substantial increase in product revenue, reaching $93.0 million in 2012, driven by higher sales volumes and the introduction of the G4 PLATINUM. However, the company continued to incur net losses, with a reported net loss of $54.5 million for the year. Despite ongoing losses, the company's cash position remained stable, and it raised capital through equity offerings. The company is focused on further development, including seeking pediatric indications for its G4 PLATINUM system, and expanding market access through strategic partnerships and reimbursement efforts.

Financial Highlights

48 data points
Beta

Revenue

$99.90M

46.6% Gross Margin

Net Income

-$54.50M

-54.6% Net Margin

EPS (Diluted)

$-0.20

Total Assets

$106.00M

Cash & Equivalents

$8.10M

Free Cash Flow

-$42.60M

Financial Statements
Beta
Revenue$99.90M
Cost of Revenue$53.30M
Gross Profit$46.60M
R&D Expenses$38.30M
SG&A Expenses$64.00M
Operating Expenses$102.30M
Operating Income-$55.70M
Interest Expense$200K
Net Income-$54.50M
EPS (Basic)$-0.20
Shares Outstanding (Basic)274.80M

Key Highlights

  • 1Launch of the G4 PLATINUM system in the U.S. in Q4 2012, a key next-generation product.
  • 2FDA approval for the G4 PLATINUM system in October 2012, enhancing product offerings.
  • 3Product revenue increased by 41% to $93.0 million in 2012, driven by increased sales volume.
  • 4Secured CE Mark approval for the G4 system in Europe and other international markets, expanding global reach.
  • 5Acquisition of SweetSpot Diabetes Care in March 2012 to bolster data management and analytics capabilities.
  • 6Continued investment in R&D, with R&D expenses increasing to $39.5 million in 2012.
  • 7Secured a $35 million loan facility in November 2012 to support operations and growth.

Frequently Asked Questions

DexCom's primary product line consists of continuous glucose monitoring (CGM) systems for ambulatory use by individuals with diabetes. Their key products include the SEVEN PLUS and the recently launched G4 PLATINUM systems.

In 2012, DexCom reported product revenue of $93.0 million, a significant increase from $65.9 million in 2011. However, the company continued to experience net losses, with a net loss of $54.5 million for the year, compared to a net loss of $44.7 million in 2011. The company's cash and cash equivalents stood at $48.7 million at year-end 2012.

Key risks for DexCom include the need for market acceptance of its products by patients and physicians, reliance on third-party payor reimbursement (with no national Medicare coverage decision yet), intense competition from established medical device companies, potential patent litigation (notably with Abbott), and the ongoing need for capital to fund research, development, and commercialization efforts, given the company's history of net losses.

DexCom plans to develop future generations of its technology for improved performance and convenience, with a focus on enabling intelligent insulin administration and developing networked platforms with open architecture. They are also seeking FDA approval for a pediatric indication for the G4 PLATINUM system and intend to seek approval for a pregnancy indication in the future.